Research progress in the treatment of diabetic retinopathy_Chinese Journal of Ocular Fundus Diseases

Authors：

Xue Chen , Xu Manhong ,  Li Xiaorong

Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin Branch of National Clinical Research Center for Ocular Disease, Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin 300384, China;

Corresponding author：

Li Xiaorong, Email: lixiaorong@tmu.edu.cn

Keywords：

Diabetic retinopathy; Drug delivery; Nano materials; Gene therapy; Review

DOI：

10.3760/cma.j.cn511434-20240923-00355

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes, which seriously threatens the vision of patients. The pathogenesis of DR Is complex and involves many pathophysiological processes. At present, the treatment methods for DR Mainly include panretinal laser photocoagulation, vitrectomy and vitreous cavity injection, etc. However, each treatment method has certain limitations. In recent years, remarkable progress has been made in the field of drug treatment of DR, especially in anti-vascular endothelial growth factor drugs, anti-inflammatory drugs, anti-oxidative stress damage drugs, neuroprotective agents, gene therapy and stem cell therapy. These drugs not only improve the effectiveness of treatment, but also expand the range of treatment options. In addition, by carrying DR Treatment drugs on carriers such as nanoparticles, hydrogels and photosensitive materials, continuous and efficient release of drugs in the eye is achieved, thereby extending the time interval of administration and reducing the need for frequent treatment of patients. In the future, based on biomarker detection technology, it is expected to promote the development of personalized and precise treatment, which can develop more accurate treatment plans for patients and improve the efficacy.

Citation： Xue Chen, Xu Manhong, Li Xiaorong. Research progress in the treatment of diabetic retinopathy. Chinese Journal of Ocular Fundus Diseases, 2025, 41(1): 56-62. doi: 10.3760/cma.j.cn511434-20240923-00355 Copy

1.	Wong TY, Cheung CM, Larsen M, et al. Diabetic retinopathy[J/OL]. Nat Rev Dis Primers, 2016, 2: 16012[2016-05-17]. https://pubmed.ncbi.nlm.nih.gov/27159554/. DOI: 10.1038/nrdp.2016.12.
2.
3.
4.
5.
6.	Lin Z, Deng A, Hou N, et al. Advances in targeted retinal photocoagulation in the treatment of diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1108394[2023-03-02]. https://pubmed.ncbi.nlm.nih.gov/36936172/. DOI: 10.3389/fendo.2023.1108394.
7.
8.
9.
10.	Pan QT, Gao ZQ, Chen XH, et al. Outcomes of a novel bubble ultra-wide field viewing system for vitreoretinal surgery[J/OL]. Acta Ophthalmol, 2022, 100(4): e1024-e1030[2021-08-17]. https://pubmed.ncbi.nlm.nih.gov/34403213/. DOI: 10.1111/aos.15006.
11.
12.
13.
14.
15.
16.
17.	Confalonieri F, Barone G, Ferraro V, et al. Early versus late pars plana vitrectomy in vitreous hemorrhage: a systematic review[J/OL]. J Clin Med, 2023, 12(20): 6652[2023-10-20]. https://pubmed.ncbi.nlm.nih.gov/37892789/. DOI: 10.3390/jcm12206652.
18.	Dervenis P, Dervenis N, Smith JM, et al. Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy[J/OL]. Cochrane Database Syst Rev, 2023, 5(5): CD008214[2023-05-31]. https://pubmed.ncbi.nlm.nih.gov/37260074/. DOI: 10.1002/14651858.CD008214.pub4.
19.	Zheng W, Chen S, Ding X, et al. Microinvasive pars plana vitrectomy versus panretinal photocoagulation in the treatment of severe non-proliferative diabetic retinopathy (the VIP study): study protocol for a randomised controlled trial[J/OL]. BMJ Open, 2021, 11(2): e043371[2021-02-22]. https://pubmed.ncbi.nlm.nih.gov/33619191/. DOI: 10.1136/bmjopen-2020-043371.
20.
21.
22.	Amato R, Rossino MG, Cammalleri M, et al. Lisosan G protects the retina from neurovascular damage in experimental diabetic retinopathy[J/OL]. Nutrients, 2018, 10(12): 1932[2018-12-05]. https://pubmed.ncbi.nlm.nih.gov/30563182/. DOI: 10.3390/nu10121932.
23.	Amato R, Melecchi A, Pucci L, et al. Liposome-mediated delivery improves the efficacy of lisosan G against retinopathy in diabetic mice[J/OL]. Cells, 2023, 12(20): 2448[2023-10-13]. https://pubmed.ncbi.nlm.nih.gov/37887292/. DOI: 10.3390/cells12202448.
24.	Li Z, Yu H, Liu C, et al. Efficiency co-delivery of ellagic acid and oxygen by a non-invasive liposome for ameliorating diabetic retinopathy[J/OL]. Int J Pharm, 2023, 641: 122987[2023-06-25]. https://pubmed.ncbi.nlm.nih.gov/37207860/. DOI: 10.1016/j.ijpharm.2023.122987.
25.	Zhou X, Lv J, Li G, et al. Rescue the retina after the ischemic injury by polymer-mediated intracellular superoxide dismutase delivery[J/OL]. Biomaterials, 2021, 268: 120600[2020-12-17]. https://pubmed.ncbi.nlm.nih.gov/33360507/. DOI: 10.1016/j.biomaterials.2020.120600.
26.
27.
28.	Liu YC, Lin YK, Lin YT, et al. Injectable, antioxidative, and tissue-adhesive nanocomposite hydrogel as a potential treatment for inner retina injuries[J/OL]. Adv Sci (Weinh), 2024, 11(11): e2308635[2024-01-17]. https://pubmed.ncbi.nlm.nih.gov/38233151/. DOI: 10.1002/advs.202308635.
29.
30.	Madadi M, Khoee S. Magnetite-based Janus nanoparticles, their synthesis and biomedical applications[J/OL]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2023, 15(6): e1908[2023-06-04]. https://pubmed.ncbi.nlm.nih.gov/37271573/. DOI: 10.1002/wnan.1908.
31.	Jia Y, Wang X, Li L, et al. Lipid nanoparticles optimized for targeting and release of nucleic acid[J/OL]. Adv Mater, 2024, 36(4): e2305300[2023-11-30]. https://pubmed.ncbi.nlm.nih.gov/37547955/. DOI: 10.1002/adma.202305300.
32.	Gu H, Chen P, Liu X, et al. Trimethylated chitosan-coated flexible liposomes with resveratrol for topical drug delivery to reduce blue-light-induced retinal damage[J/OL]. Int J Biol Macromol, 2023, 252: 126480[2023-12-01]. https://pubmed.ncbi.nlm.nih.gov/37634770/. DOI: 10.1016/j.ijbiomac.2023.126480.
33.	Rashki S, Asgarpour K, Tarrahimofrad H, et al. Chitosan-based nanoparticles against bacterial infections[J/OL]. Carbohydr Polym, 2021, 251: 117108[2021-01-01]. https://pubmed.ncbi.nlm.nih.gov/33142645/. DOI: 10.1016/j.carbpol.2020.117108.
34.
35.
36.
37.	Alfieri ML, Weil T, Ng DYW, et al. Polydopamine at biological interfaces[J/OL]. Adv Colloid Interface Sci, 2022, 305: 102689[2022-04-30]. https://pubmed.ncbi.nlm.nih.gov/35525091/. DOI: 10.1016/j.cis.2022.102689.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.	Chen W, Cui W, Wu J, et al. Blocking IL-6 signaling improves glucose tolerance via SLC39A5-mediated suppression of glucagon secretion[J/OL]. Metabolism, 2023, 146: 155641[2023-06-26]. https://pubmed.ncbi.nlm.nih.gov/37380017/. DOI: 10.1016/j.metabol.2023.155641.
50.
51.
52.
53.
54.
55.	Massoumi H, Amin S, Soleimani M, et al. Extracellular-vesicle-based therapeutics in neuro-ophthalmic disorders[J/OL]. Int J Mol Sci, 2023, 24(10): 9006[2023-05-19]. https://pubmed.ncbi.nlm.nih.gov/37240353/. DOI: 10.3390/ijms24109006.
56.	Yi W, Xue Y, Qing W, et al. Effective treatment of optic neuropathies by intraocular delivery of MSC-sEVs through augmenting the G-CSF-macrophage pathway[J/OL]. Proc Natl Acad Sci USA, 2024, 121(6): e2305947121[2024-02-06]. https://pubmed.ncbi.nlm.nih.gov/38289952/. DOI: 10.1073/pnas.2305947121.
57.
58.	Chung SH, Sin TN, Ngo T, et al. CRISPR technology for ocular angiogenesis[J/OL]. Front Genome Ed, 2020, 2: 594984[2022-11-22]. https://pubmed.ncbi.nlm.nih.gov/34713223/. DOI: 10.3389/fgeed.2020.594984.
59.	Liu K, Gao X, Hu C, et al. Capsaicin ameliorates diabetic retinopathy by inhibiting poldip2-induced oxidative stress[J/OL]. Redox Biol, 2022, 56: 102460[2022-09-03]. https://pubmed.ncbi.nlm.nih.gov/36088760/. DOI: 10.1016/j.redox.2022.102460.
60.
61.	Haurigot V, Villacampa P, Ribera A, et al. Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy[J/OL]. PLoS One, 2012, 7(7): e41511[2012-07-20]. https://pubmed.ncbi.nlm.nih.gov/22911805/. DOI: 10.1371/journal.pone.0041511.
62.
63.
64.
65.
66.
67.
68.

1. Wong TY, Cheung CM, Larsen M, et al. Diabetic retinopathy[J/OL]. Nat Rev Dis Primers, 2016, 2: 16012[2016-05-17]. https://pubmed.ncbi.nlm.nih.gov/27159554/. DOI: 10.1038/nrdp.2016.12.
2.
3.
4.
5.
6. Lin Z, Deng A, Hou N, et al. Advances in targeted retinal photocoagulation in the treatment of diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1108394[2023-03-02]. https://pubmed.ncbi.nlm.nih.gov/36936172/. DOI: 10.3389/fendo.2023.1108394.
7.
8.
9.
10. Pan QT, Gao ZQ, Chen XH, et al. Outcomes of a novel bubble ultra-wide field viewing system for vitreoretinal surgery[J/OL]. Acta Ophthalmol, 2022, 100(4): e1024-e1030[2021-08-17]. https://pubmed.ncbi.nlm.nih.gov/34403213/. DOI: 10.1111/aos.15006.
11.
12.
13.
14.
15.
16.
17. Confalonieri F, Barone G, Ferraro V, et al. Early versus late pars plana vitrectomy in vitreous hemorrhage: a systematic review[J/OL]. J Clin Med, 2023, 12(20): 6652[2023-10-20]. https://pubmed.ncbi.nlm.nih.gov/37892789/. DOI: 10.3390/jcm12206652.
18. Dervenis P, Dervenis N, Smith JM, et al. Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy[J/OL]. Cochrane Database Syst Rev, 2023, 5(5): CD008214[2023-05-31]. https://pubmed.ncbi.nlm.nih.gov/37260074/. DOI: 10.1002/14651858.CD008214.pub4.
19. Zheng W, Chen S, Ding X, et al. Microinvasive pars plana vitrectomy versus panretinal photocoagulation in the treatment of severe non-proliferative diabetic retinopathy (the VIP study): study protocol for a randomised controlled trial[J/OL]. BMJ Open, 2021, 11(2): e043371[2021-02-22]. https://pubmed.ncbi.nlm.nih.gov/33619191/. DOI: 10.1136/bmjopen-2020-043371.
20.
21.
22. Amato R, Rossino MG, Cammalleri M, et al. Lisosan G protects the retina from neurovascular damage in experimental diabetic retinopathy[J/OL]. Nutrients, 2018, 10(12): 1932[2018-12-05]. https://pubmed.ncbi.nlm.nih.gov/30563182/. DOI: 10.3390/nu10121932.
23. Amato R, Melecchi A, Pucci L, et al. Liposome-mediated delivery improves the efficacy of lisosan G against retinopathy in diabetic mice[J/OL]. Cells, 2023, 12(20): 2448[2023-10-13]. https://pubmed.ncbi.nlm.nih.gov/37887292/. DOI: 10.3390/cells12202448.
24. Li Z, Yu H, Liu C, et al. Efficiency co-delivery of ellagic acid and oxygen by a non-invasive liposome for ameliorating diabetic retinopathy[J/OL]. Int J Pharm, 2023, 641: 122987[2023-06-25]. https://pubmed.ncbi.nlm.nih.gov/37207860/. DOI: 10.1016/j.ijpharm.2023.122987.
25. Zhou X, Lv J, Li G, et al. Rescue the retina after the ischemic injury by polymer-mediated intracellular superoxide dismutase delivery[J/OL]. Biomaterials, 2021, 268: 120600[2020-12-17]. https://pubmed.ncbi.nlm.nih.gov/33360507/. DOI: 10.1016/j.biomaterials.2020.120600.
26.
27.
28. Liu YC, Lin YK, Lin YT, et al. Injectable, antioxidative, and tissue-adhesive nanocomposite hydrogel as a potential treatment for inner retina injuries[J/OL]. Adv Sci (Weinh), 2024, 11(11): e2308635[2024-01-17]. https://pubmed.ncbi.nlm.nih.gov/38233151/. DOI: 10.1002/advs.202308635.
29.
30. Madadi M, Khoee S. Magnetite-based Janus nanoparticles, their synthesis and biomedical applications[J/OL]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2023, 15(6): e1908[2023-06-04]. https://pubmed.ncbi.nlm.nih.gov/37271573/. DOI: 10.1002/wnan.1908.
31. Jia Y, Wang X, Li L, et al. Lipid nanoparticles optimized for targeting and release of nucleic acid[J/OL]. Adv Mater, 2024, 36(4): e2305300[2023-11-30]. https://pubmed.ncbi.nlm.nih.gov/37547955/. DOI: 10.1002/adma.202305300.
32. Gu H, Chen P, Liu X, et al. Trimethylated chitosan-coated flexible liposomes with resveratrol for topical drug delivery to reduce blue-light-induced retinal damage[J/OL]. Int J Biol Macromol, 2023, 252: 126480[2023-12-01]. https://pubmed.ncbi.nlm.nih.gov/37634770/. DOI: 10.1016/j.ijbiomac.2023.126480.
33. Rashki S, Asgarpour K, Tarrahimofrad H, et al. Chitosan-based nanoparticles against bacterial infections[J/OL]. Carbohydr Polym, 2021, 251: 117108[2021-01-01]. https://pubmed.ncbi.nlm.nih.gov/33142645/. DOI: 10.1016/j.carbpol.2020.117108.
34.
35.
36.
37. Alfieri ML, Weil T, Ng DYW, et al. Polydopamine at biological interfaces[J/OL]. Adv Colloid Interface Sci, 2022, 305: 102689[2022-04-30]. https://pubmed.ncbi.nlm.nih.gov/35525091/. DOI: 10.1016/j.cis.2022.102689.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49. Chen W, Cui W, Wu J, et al. Blocking IL-6 signaling improves glucose tolerance via SLC39A5-mediated suppression of glucagon secretion[J/OL]. Metabolism, 2023, 146: 155641[2023-06-26]. https://pubmed.ncbi.nlm.nih.gov/37380017/. DOI: 10.1016/j.metabol.2023.155641.
50.
51.
52.
53.
54.
55. Massoumi H, Amin S, Soleimani M, et al. Extracellular-vesicle-based therapeutics in neuro-ophthalmic disorders[J/OL]. Int J Mol Sci, 2023, 24(10): 9006[2023-05-19]. https://pubmed.ncbi.nlm.nih.gov/37240353/. DOI: 10.3390/ijms24109006.
56. Yi W, Xue Y, Qing W, et al. Effective treatment of optic neuropathies by intraocular delivery of MSC-sEVs through augmenting the G-CSF-macrophage pathway[J/OL]. Proc Natl Acad Sci USA, 2024, 121(6): e2305947121[2024-02-06]. https://pubmed.ncbi.nlm.nih.gov/38289952/. DOI: 10.1073/pnas.2305947121.
57.
58. Chung SH, Sin TN, Ngo T, et al. CRISPR technology for ocular angiogenesis[J/OL]. Front Genome Ed, 2020, 2: 594984[2022-11-22]. https://pubmed.ncbi.nlm.nih.gov/34713223/. DOI: 10.3389/fgeed.2020.594984.
59. Liu K, Gao X, Hu C, et al. Capsaicin ameliorates diabetic retinopathy by inhibiting poldip2-induced oxidative stress[J/OL]. Redox Biol, 2022, 56: 102460[2022-09-03]. https://pubmed.ncbi.nlm.nih.gov/36088760/. DOI: 10.1016/j.redox.2022.102460.
60.
61. Haurigot V, Villacampa P, Ribera A, et al. Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy[J/OL]. PLoS One, 2012, 7(7): e41511[2012-07-20]. https://pubmed.ncbi.nlm.nih.gov/22911805/. DOI: 10.1371/journal.pone.0041511.
62.
63.
64.
65.
66.
67.
68.

Previous Article
弓形体性视网膜脉络膜炎
Next Article
Research progress on the effects of different dosing regimens of anti-vascular endothelial growth factor drugs on diabetic retinopathy

Chinese Journal of Ocular Fundus Diseases

Research progress in the treatment of diabetic retinopathy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content